Studying Complement Inhibition in Early, Newly Developing Septic Organ Dysfunction

Summary

The trial enrolls patients with early severe sepsis or septic shock displaying at least one newly developed organ dysfunction and showing clinical evidence of pulmonary or abdominal infection. The primary goal of the trial is to assess the pharmacokinetics and pharmacodynamics of the new monoclonal antibody CaCP29 and to characterize safety and tolerability as well as evaluate parameters of efficacy.

Timeline

Start

2014-04

Primary completion

2015-12

Completion

2015-12

Drugs

Indications